Objectives: In shared decision making it is important to adequately, timely and actively involve patients in treatment decisions. Sharing prognostic information can be of key importance. This study describes whether and how prognostic information on life expectancy is included during communication on diagnosis and treatment plans between physicians and head and neck (H&N) oncologic patients in different phases of disease.
Methods: A descriptive, qualitative study was performed of n = 23 audiotaped physician-patient conversations in which both palliative and curative treatment options were discussed and questions on prognosis were expected. Verbatim transcribed consultations were systematically analyzed. A distinction was made between prognostic information that was provided (a) quantitatively: by giving numerical probability estimates, such as percentages or years or (b) qualitatively: through the use of words such as ‘most likely’ or ‘highly improbable’.
Results: In all consultations, H&N surgeons provided some prognostic information. In 5.9% of the provided prognostic information, a quantitative method was used. In 94.1% prognostic information was provided qualitatively, using six identified approaches. H&N surgeons possibly affect patients’ perception of prognostic content with two identified communication styles: directive (more physician-centered) and affective (more patient-centered).
Conclusion: This study is first in providing examples of how H&N surgeons communicate with their patients regarding prognosis in all stages of disease. They often exclude specific prognostic information. The study outcomes can be used as a first step in developing a guideline for sharing prognostic information in H&N oncologic patients, in order enable the process of shared decision making.

, , , ,
doi.org/10.1016/j.oraloncology.2018.07.014, hdl.handle.net/1765/109467
Oral Oncology
Department of Otorhinolaryngology

Dronkers, E., Hoesseini, A., de Boer, M., & Offerman, M. (2018). Communication of prognosis in head and neck cancer patients. Oral Oncology, 84, 76–81. doi:10.1016/j.oraloncology.2018.07.014